Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
Sebastien Lobet, PhD at Saint-Luc University Clinics Cliniques, Co-founder of Activlim-Hemo, shared on LinkedIn:
”I had the honor of being invited to the Nordic Baltic Haemophilia Nurse and Physiotherapy Meeting, held over the past two days in Oslo.
I presented the ACTIVLIM-Hemo scale, a tool to assess activity limitations in adults with haemophilia, developed using a robust Rasch-based methodology.
The scale is unidimensional, linear, and reproducible, providing a reliable measure of functional performance.
ACTIVLIM-Hemo has been translated into 11 languages, with 5 already available.
It is freely accessible to all clinicians wishing to evaluate their patients’ activity limitations.
Developed by Prof. Massimo Penta (Arsalis and UCLouvain) and the Haematology Department of the Saint-Luc University Clinics Cliniques.
References:
Lobet S et al., Haemophilia, 2024. DOI: 10.1111/hae.14954
Lobet S et al., Haemophilia, 2023. DOI: 10.1111/hae.14705”
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis